论文部分内容阅读
selexipag是一种口服的选择性前列环素受体激动剂,可松弛血管壁平滑肌,扩张血管,降低肺动脉血管的压力。2015年12月本品由美国FDA经标准审评程序获准上市,用于肺动脉高压的治疗。与安慰剂相比,本品可有效降低肺动脉高压的住院率和疾病恶化风险。本文对其作用机制、药动学、药效学、临床试验、用法与用量、药物相互作用、安全性以及特殊人群用药等方面做一综述。
Selexipag, an oral, selective prostacyclin receptor agonist, relaxes the smooth muscle lining of blood vessels, dilates blood vessels and decreases the pressure on the pulmonary arteries. December 2015 This product was approved by the US FDA for standard review and approval for the treatment of pulmonary hypertension. Compared with placebo, this product can effectively reduce the hospitalization rate of pulmonary hypertension and the risk of disease progression. This article reviews its mechanism of action, pharmacokinetics, pharmacodynamics, clinical trials, usage and dosage, drug interactions, safety and medication for special populations.